[A combined sulbactam/cefoperazone and amikacin therapy for the treatment of infections complicated with hematological diseases].
Eighty-six patients with infections associated with hematological disorders were treated with sulbactam/cefoperazone (SBT/CPZ) and amikacin (AMK). Among 71 evaluable cases, 30 cases had acute non-lymphocytic leukemia, 3 acute lymphoblastic leukemia, 25 malignant lymphoma, and 7 myelodysplastic syndrome as underlying diseases. Excellent responses were obtained in 33 cases (46.5%) and good responses in 14 cases (19.7%), with an overall efficacy rate of 66.2%. The efficacy rate among cases with suspected sepsis was 72.5%. This treatment was also effective in 69.2% of cases in which neutrophil counts were less than 500/microliter through the course of administration. The eradication rate was 83.3% among 6 strains in which Gram-negative rods were detected. Side effects were minimum; skin rash in 1 case, slight elevation of APTT in 3 and slight elevation of total bilirubin in 1. Thus, this combination antibacterial chemotherapy is an effective and safe regimen for the treatment of severe infections in patients with hematological disorders.
Third Department of Internal Medicine, Kyoto Prefectural University of Medicine.
T
T
Takashima
S
S
Tsuda
S
S
Misawa
S
S
Horiike
Y
Y
Kuzuyama
K
K
Hirakawa
H
H
Nakai
T
T
Seriu
S
S
Tanaka
K
K
Nishida
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000583:Amikacin / Q000008:administration & dosage; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D002438:Cefoperazone / Q000008:administration & dosage; D004338:Drug Combinations; D004359:Drug Therapy, Combination / Q000008:administration & dosage*; D005260:Female; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D016867:Immunocompromised Host; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009504:Neutrophils; D013407:Sulbactam / Q000008:administration & dosage
D004338:Drug Combinations; D002438:Cefoperazone; D000583:Amikacin; D013407:Sulbactam